- $3.71m
- $30.46m
- $11.69m
- 29
- 78
- 37
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.38 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -87.74% | ||
| Return on Equity | -522.6% | ||
| Operating Margin | -253.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.38 | 4.33 | 11.96 | 9.76 | 11.69 | 15.84 | 22.17 | 15.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
Directors
- James Bochnowski NEC (77)
- Lisa Conte PRE (61)
- Carol Lizak CFO (57)
- Karen Brunke EVP
- Jonathan Wolin CCO (59)
- Chip Whitlow DMK
- Steven King SEC (62)
- Gregory Divis IND (54)
- John Micek IND (68)
- Jonathan Siegel IND (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 6th, 2013
- Public Since
- May 13th, 2015
- No. of Shareholders
- 17
- No. of Employees
- 49
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 674,052
- Address
- 200 PINE STREET SUITE 400, SAN FRANCISCO, 94104
- Web
- https://jaguar.health/
- Phone
- +1 4153718300
- Auditors
- RBSM LLP
Upcoming Events for JAGX
Jaguar Health Inc Annual Shareholders Meeting
Q2 2025 Jaguar Health Inc Earnings Release
Similar to JAGX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Jaguar Health share price?
As of Today at 21:24 UTC, shares in Jaguar Health are trading at $5.51. This share price information is delayed by 15 minutes.
How has the Jaguar Health share price performed this year?
Shares in Jaguar Health last closed at $5.51 and the price had moved by -97.77% over the past 365 days. In terms of relative price strength the Jaguar Health share price has underperformed the S&P500 Index by -97.91% over the past year.
What are the analyst and broker recommendations for Jaguar Health?
The overall consensus recommendation for Jaguar Health is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Jaguar Health dividend yield?
Jaguar Health does not currently pay a dividend.
Does Jaguar Health pay a dividend?
Jaguar Health does not currently pay a dividend.
When does Jaguar Health next pay dividends?
Jaguar Health does not currently pay a dividend.
How do I buy Jaguar Health shares?
To buy shares in Jaguar Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Jaguar Health?
As of the previous close price of $5.51, shares in Jaguar Health had a market capitalisation of $3.71m.
Where are Jaguar Health shares listed?
Here are the trading details for Jaguar Health:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: JAGX
What kind of share is Jaguar Health?
Based on an overall assessment of its quality, value and momentum Jaguar Health is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Jaguar Health share price forecast for 2025?
The analyst consensus target price for shares in Jaguar Health is $150.00. That is 2622.32% above the last closing price of $5.51.
Analysts covering Jaguar Health currently have a consensus Earnings Per Share (EPS) forecast of -$51.50 for the next financial year.
Find out moreWhat is the trend in the Jaguar Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jaguar Health. Over the past six months, its share price has underperformed the S&P500 Index by -79.98%.
As of the last closing price of $5.51, shares in Jaguar Health were trading -80.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Jaguar Health PE Ratio?
The Jaguar Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Jaguar Health?
Jaguar Health's management team is headed by:
- James Bochnowski - NEC
- Lisa Conte - PRE
- Carol Lizak - CFO
- Karen Brunke - EVP
- Jonathan Wolin - CCO
- Chip Whitlow - DMK
- Steven King - SEC
- Gregory Divis - IND
- John Micek - IND
- Jonathan Siegel - IND